Bio-Techne Corporation vs Galapagos NV: SG&A Expense Trends

SG&A Expense Trends: Bio-Techne Corporation vs. Galapagos NV

In the dynamic world of biotechnology, understanding financial trends is crucial for investors and stakeholders. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent biotech companies: Bio-Techne Corporation and Galapagos NV, from 2014 to 2023.

Bio-Techne Corporation has shown a consistent upward trajectory in SG&A expenses, with a remarkable 550% increase from 2014 to 2023. This growth reflects the company's expanding operations and strategic investments. In contrast, Galapagos NV experienced a more volatile pattern, with a peak in 2022, marking a 2,500% increase from 2014, before a significant drop in 2023.

The data highlights Bio-Techne's steady growth strategy, while Galapagos NV's fluctuations suggest a more dynamic approach. These insights provide a window into the operational strategies of these biotech giants, offering valuable information for potential investors.